Feb 7, 2003
Biotechnology company Biogen Inc. said on Friday its multiple sclerosis drug Avonex (interferon beta-1a) has been approved by the US Food and Drug Administration for treatment of patients with early signs of multiple sclerosis.
Until now, standard practice had been to treat multiple sclerosis only after a patient experienced at least two clinical attacks. But, the FDA said it will now allow the use of Avonex for patients who have had a single attack if a brain scan shows abnormalities characteristic of multiple sclerosis.
This use of the drug was approved in Europe last year. Approval in the
United States was based on a three-year research study, Biogen said.
© 2003 Reuters Ltd